Patrick Daly

Lung Cancers Today

Researchers performed a retrospective analysis to identify risk factors and subsequently develop a predictive scoring model for pulmonary embolisms in patients with lung cancer. The initial analyses identified 7 parameters that would inform the nomogram scoring system.In the report, published in&nbsp;Clinical and Applied Thrombosis/Hemostasis, the study&rsquo;s lead author, Ning Zhu, wrote that the team&rsquo;s scoring system demonstrated &ldquo;good accuracy and discrimination&rdquo; for distinguishing between <a href="https://www.docwirenews.com/docwire-pick/nivolumab-with-ipilimumab-in-metastatic-nsclc/">patients with lung cancer</a> who did or did not have a pulmonary embolism, and was also effective for predicting risk of pulmonary embolism in patients with lung cancer.<h2>Nomogram Risk Scoring for Pulmonary Embolism in Lung Cancer</h2>The authors&rsquo; retrospective analysis included clinical and laboratory data of 900 patients with lung cancer, both with and without pulmonary embolisms. The cohort was divided 7:3 into internal development and validation groups and researchers used logistic regression models to construct a diagnostic model of the nomogram scoring system.The 7 variables used to develop the predictive model were:<ul>
<li>Adenocarcinoma</li>
<li>Stage III-IV disease</li>
<li>Indwelling central venous catheter</li>
<li>Chemotherapy</li>
<li>Serum albumin levels</li>
<li>Serum hemoglobin levels</li>
<li>Serum D-dimer levels</li>
</ul>In the development cohort, authors calculated the diagnostic model had an area under the receiver operating characteristic curve (AUC) of 0.918 (95% CI, 0.893-0.943), and sensitivity and specificity of 88.5% and 80.5%, respectively, for identifying patients with <a href="https://medlineplus.gov/pulmonaryembolism.html" target="_blank" rel="noopener">pulmonary embolism</a>.In the internal validation group, investigators reported the model had an AUC of 0.921 (95% CI, 0.884-0.953) with a sensitivity of 90.5% and specificity of 80.4%. Additionally, in an external validation cohort of 108 patients, the model reportedly had an AUC, sensitivity, and specificity of 0.929 (95% CI, 0.875-0.983), 85.0%, and 87.5%, respectively.While the authors acknowledged their retrospective analysis-based nomogram scoring system requires validation in larger, prospective studies, they nonetheless suggested their predictive model can help clinicians screen patients with lung cancer for pulmonary embolism.Find More <a href="https://www.docwirenews.com/lung-cancer-resource-center/">Recent Studies on Patients With Lung Cancer</a>

Laura Litwin

How Do Immune Checkpoint Inhibitors Affect Quality of Life in Real-World Patients With NSCLC?

ELCC 2025

Cecilia Brown

Data on RNA-Based Cancer Vaccine Plus Cemiplimab for NSCLC Presented at AACR 2025

Non-Small Cell Lung Cancer

Mara B. Antonoff, MD, FACS

Surgery in Oligometastatic Disease: Dr. Antonoff Shares Insights

Lung Cancer

Phase 3 SKYSCRAPER-01 Study: Final PFS, OS Analyses Presented at AACR 2025

Immunotherapy in NSCLC

Beamion LUNG-1: Zongertinib Shows ‘Significant’ Activity in Patients With NSCLC Harboring HER2 Mutations

Conference Coverage

Zoldonrasib Shows ‘Encouraging’ Activity in Patients With NSCLC Harboring KRAS G12D Mutation

KRAS+ NSCLC

Latest News

Predictive Model for Pulmonary Embolism Risk in Lung Cancer

Researchers performed a retrospective analysis to identify risk factors and subsequently develop a predictive scoring model for pulmonary embolisms in patients with lung ...